DarioHealth (NASDAQ:DRIO) Stock Price Crosses Below Fifty Day Moving Average – Time to Sell?

DarioHealth Corp. (NASDAQ:DRIO) crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $7.80 and traded as low as $7.30. DarioHealth shares last traded at $7.51, with a volume of 12,963 shares.

Analyst Ratings Changes

DRIO has been the subject of a number of research reports. TD Cowen reiterated a “hold” rating and issued a $11.00 price target on shares of DarioHealth in a research note on Wednesday, May 13th. Stifel Nicolaus reiterated a “buy” rating and issued a $10.00 price target on shares of DarioHealth in a research note on Thursday, May 14th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, DarioHealth presently has an average rating of “Hold” and an average target price of $10.50.

DarioHealth Stock Performance

The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.62 and a current ratio of 3.07. The company has a 50 day moving average price of $7.80 and a 200 day moving average price of $10.17. The company has a market capitalization of $54.90 million, a price-to-earnings ratio of -0.85 and a beta of 1.09.

Hedge Funds Weigh In On DarioHealth

Large investors have recently added to or reduced their stakes in the business. Kestra Advisory Services LLC purchased a new position in shares of DarioHealth in the 4th quarter worth approximately $35,000. Geode Capital Management LLC boosted its stake in shares of DarioHealth by 167.9% in the 4th quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock worth $564,000 after buying an additional 31,063 shares during the last quarter. Finally, XTX Topco Ltd boosted its stake in shares of DarioHealth by 229.0% in the 2nd quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock worth $42,000 after buying an additional 43,513 shares during the last quarter. Institutional investors own 33.39% of the company’s stock.

DarioHealth Company Profile

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.